{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T01:01:50Z","timestamp":1760576510171,"version":"build-2065373602"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,15]]},"DOI":"10.7759\/cureus.94653","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:47:52Z","timestamp":1760557672000},"source":"Crossref","is-referenced-by-count":0,"title":["Unraveling Peritoneal Mesothelioma: A Case-Based Discussion on Diagnosis and Management"],"prefix":"10.7759","author":[{"given":"Othmane","family":"Zouiten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Latifa","family":"Azarou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasnaa","family":"Hadiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanane","family":"Rais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rhizlane","family":"Belbaraka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/10408440903044928","article-title":"Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005","volume":"39","author":"Price B","year":"2009","unstructured":"Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009, 39:576-88. 10.1080\/10408440903044928","journal-title":"Crit Rev Toxicol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5858\/2008-132-397-AOITTD","article-title":"Application of immunohistochemistry to the diagnosis of malignant mesothelioma","volume":"132","author":"Marchevsky AM","year":"2008","unstructured":"Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008, 132:397-401. 10.5858\/2008-132-397-AOITTD","journal-title":"Arch Pathol Lab Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13714","article-title":"A novel malignant peritoneal mesothelioma with STRN exon 2 and ALK exon 20: a case report and literature review","volume":"26","author":"Miyagawa C","year":"2021","unstructured":"Miyagawa C, Takaya H, Sakai K, et al.. A novel malignant peritoneal mesothelioma with STRN exon 2 and ALK exon 20: a case report and literature review. Oncologist. 2021, 26:356-61. 10.1002\/onco.13714","journal-title":"Oncologist"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/18.2.320","article-title":"Mesothelioma in South Africa, 1976-84: incidence and case characteristics","volume":"18","author":"Zwi AB","year":"1989","unstructured":"Zwi AB, Reid G, Landau SP, Kielkowski D, Sitas P, Becklake MR. Mesothelioma in South Africa, 1976-84: incidence and case characteristics. Int J Epidemiol. 1989, 18:320-9. 10.1093\/ije\/18.2.320","journal-title":"Int J Epidemiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.48408\/IMIST.PRSM\/mm-v22i2.767","article-title":"The malignant peritoneal mesothelioma (about one case) (Article in French)","volume":"22","author":"Benamour H","year":"2000","unstructured":"Benamour H, Jroundi L, Chat I, Chellaoui M. The malignant peritoneal mesothelioma (about one case) (Article in French). Maroc Med. 2000, 22:10.48408\/IMIST.PRSM\/mm-v22i2.767","journal-title":"Maroc Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4041-7","article-title":"Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures","volume":"22","author":"Low RN","year":"2015","unstructured":"Low RN, Barone RM, Lucero J. Comparison of MRI and CT for predicting the Peritoneal Cancer Index (PCI) preoperatively in patients being considered for cytoreductive surgical procedures. Ann Surg Oncol. 2015, 22:1708-15. 10.1245\/s10434-014-4041-7","journal-title":"Ann Surg Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4103\/ija.IJA_765_19","article-title":"Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC)","volume":"63","author":"Solanki SL","year":"2019","unstructured":"Solanki SL, Mukherjee S, Agarwal V, et al.. Society of Onco-Anaesthesia and Perioperative Care consensus guidelines for perioperative management of patients for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Indian J Anaesth. 2019, 63:972-87. 10.4103\/ija.IJA_765_19","journal-title":"Indian J Anaesth"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3816\/CLC.2005.n.020","article-title":"Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program","volume":"7","author":"J\u00e4nne PA","year":"2005","unstructured":"J\u00e4nne PA, Wozniak AJ, Belani CP, et al.. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer. 2005, 7:40-6. 10.3816\/CLC.2005.n.020","journal-title":"Clin Lung Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.19934","article-title":"Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma","volume":"4","author":"Raghav K","year":"2021","unstructured":"Raghav K, Liu S, Overman M, Morani A, Willette A, Fournier K, Varadhachary G. Clinical efficacy of immune checkpoint inhibitors in patients with advanced malignant peritoneal mesothelioma. JAMA Netw Open. 2021, 4:e2119934. 10.1001\/jamanetworkopen.2021.19934","journal-title":"JAMA Netw Open"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3358-y","article-title":"Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis","volume":"21","author":"Magge D","year":"2014","unstructured":"Magge D, Zenati MS, Austin F, et al.. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol. 2014, 21:1159-65. 10.1245\/s10434-013-3358-y","journal-title":"Ann Surg Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/409505-unraveling-peritoneal-mesothelioma-a-case-based-discussion-on-diagnosis-and-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T19:47:53Z","timestamp":1760557673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/409505-unraveling-peritoneal-mesothelioma-a-case-based-discussion-on-diagnosis-and-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.94653","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}